1. The role of CpG island methylator phenotype in the clinical course of hepatocellular carcinoma
- Author
-
Lei Cai, Jun Yan, Jiahong Dong, Zhongsong Man, Qian Lu, and Lu Gao
- Subjects
Statistics and Probability ,Oncology ,Supplementary data ,medicine.medical_specialty ,CpG Island Methylator Phenotype ,Receiver operating characteristic ,business.industry ,Clinical course ,Methylation ,medicine.disease ,Biochemistry ,Computer Science Applications ,Computational Mathematics ,Computational Theory and Mathematics ,CpG site ,Internal medicine ,Hepatocellular carcinoma ,medicine ,Aberrant DNA Methylation ,business ,Molecular Biology - Abstract
Motivation Aberrant DNA methylation is strongly associated with heterogeneity in tumors. This study investigated the prognostic value of CpG island methylator phenotype in hepatocellular carcinoma (HCC). Results A total of 319 HCC samples with 21 121 CpG sites were included in this study and 215 disease-free survival (DFS) and overall survival (OS)-related CpG sites were identified. These CpG sites were divided into seven clusters by using consensus clustering method. Cluster 4, which constructed the prognostic prediction model as the seed cluster to evaluate survival risk for DFS and OS of HCC patients, had the lowest methylation level with the worse prognosis. The low-risk group patients had a significantly prolonged DFS and OS than the patients in the high-risk group (P = 0.008 and P Availability and implementation The code of the analysis is available at https://www.bioconductor.org. Supplementary information Supplementary data are available at Bioinformatics online.
- Published
- 2021